Alamo Pharma Services launches Alamo Recruitment Services

DOYLESTOWN, Pa. (August 16, 2017) – Alamo Pharma Services, an established leader in attracting exceptional talent in the pharmaceutical and biotech industries, has formed a specialized division of the company that offers partner organizations recruiting services to place the right people with the right attitude and the right talent in the right position within the client company.

“The investment companies make in bringing products to market is not fully realized until they put that product in the best position to be promoted to healthcare providers,” says Amy Peek...

Alamo Pharma Services Chief Operating Officer named to PharmaVOICE 100 most inspiring people

DOYLESTOWN, Pa. (August 2, 2017) – Alamo Pharma Services, Inc. (“Alamo”) is pleased to announce that its Chief Operating Officer, Peter Marchesini, has been named to PharmaVOICE magazine’s annual list of 100 most inspiring people in the life sciences industry for the second time. Marchesini previously received this prestigious distinction in 2009. Individuals named to PharmaVOICE 100 are leaders who drive the industry forward and inspire others through their innovative contributions and effective leadership style. Because PharmaVOICE 100 is a...

Two Mission executives named PharmaVOICE 100 most inspiring people and a third receives prestigious Red Jacket Award

SAN ANTONIO (August 1, 2017) – Mission Pharmacal Company (“Mission”) announced today that its President of Commercial Operations, Terry Herring, and Senior Vice President of Corporate Marketing, Natalie Sirjuesingh, were honored in the 2017 July/August issue of PharmaVOICE magazine for their contributions to the life sciences industry. Alamo Pharma Services (“Alamo”) Chief Operating Officer Peter Marchesini was also honored in the issue for his work with Alamo, a member of the Mission Family of Companies.

Mission Family of Companies’ Espada Dermatology continues specialized therapeutic service line growth

SAN ANTONIO (July 26, 2017) – For many years, San Antonio-based Mission Pharmacal Company (“Mission”) has manufactured and marketed highly specialized dermatology products. Utilizing only the finest ingredients, these products help ease patient suffering related to specific dermatologic conditions including acne, rosacea, seborrheic dermatitis, and other steroid responsive skin conditions. In 2016, the company acquired Glyderm® skin care products and formed Espada Dermatology, Inc. (“Espada”) to market the esthetic dermatology product line. A talented team of...

Alamo Pharma Services Chief Operating Officer to Share Insights During CBI’s 6th Annual Bio/Pharma Product Forecasting & Analytics Summit

DOYLESTOWN, Pa. (June 14, 2017) – Peter Marchesini, Chief Operating Officer of Alamo Pharma Services (“Alamo”), will participate in CBI’s sixth annual “Bio/Pharma Product Forecasting and Analytics Summit” taking place in Philadelphia on June 15 and 16, 2017. The focus of the summit is to help attendees improve forecasting to optimize revenue potential for pipeline and inline products. Marchesini, along with Noetyx President and Chief Executive Officer  Lenny Vicciardo, will be leading a discussion on “Building an Organizational Infrastructure Based on Long-Term Forecasts...

Alamo Pharma Services and BexR Logistix Add Top Executive to Help with Sales Operations and Business Development Efforts

SAN ANTONIO (June 8, 2017) – Alamo Pharma Services, Inc. (“Alamo”) and BexR Logistix, LLC (“BexR”) continue to grow with the addition of Thomas M. (Tom) Sottile as Executive Director, Sales and Business Development. Tom will contribute to the sales operations and business development efforts for two of the Mission Family of Companies. Having been in the industry for more than 25 years, Sottile has experienced career growth on both the manufacturing and services sides of the pharmaceutical industry. Sottile brings strong leadership and business development skills and...

Alamo Pharma Services Sales Training Leader to Participate in 2017 LTEN Conference Panel Discussion

DOYLESTOWN, PA (June 5, 2017) – Denise Fullowan, Executive Director, Training & Development of Alamo Pharma Services, Inc. (“Alamo”), will participate in the Life Sciences Trainers & Educators Network (“LTEN”) Conference, in Nashville, Tennessee, on Tuesday, June 6, 2017. The conference, which commences on June 5 and runs through June 8, is being held for its 46th year and is the only conference developed entirely by and for life sciences trainers.

...

ProSolus Seeks Higher Utilization of Transdermal Drug Delivery Technology

MIAMI, Fla. (April 25, 2017) – ProSolus, Inc. (“ProSolus”) is doubling down on its efforts to expand the utilization of transdermal drug delivery technologies. Today Mission Pharmacal Company (“Mission”) and ProSolus announced the expanded manufacturing capabilities of ProSolus and an increased emphasis on the company’s overall commercialization efforts. ProSolus, a wholly owned subsidiary of Mission, offers unrivaled expertise in the custom development and manufacturing of sophisticated and convenient transdermal and trans-mucosal drug delivery products to treat a variety...

Alamo Pharma Services and BexR Logistix Leaders to Participate in the Synergistix Solutions through Partnerships Conference Panel Discussions

SAN ANTONIO (March 7, 2017) – Peter Marchesini, Chief Operating Officer of Alamo Pharma Services, Inc. (“Alamo”), and Daniel J. Harmon, Jr., General Manager and Vice President of Business Development at BexR Logistix, LLC (“BexR”), will participate in the 13th annual Synergistix Solutions through Partnerships Conference in Pompano Beach, Florida, March 8-10, 2017. The conference is an invitation only event for pharmaceutical and life sciences executives, that focuses on key aspects of product commercialization and operations in the pharmaceutical and medical device arena....

Napo Pharmaceuticals Signs Agreement with Alamo Pharma Services to Launch National Sales Force for Mytesi™

SAN FRANCISCO, CA (February 28, 2017) — Napo Pharmaceuticals, Inc., a company focused on the development and commercialization of proprietary pharmaceuticals for the global marketplace from plants traditionally used in rainforest areas, announces today that it has signed an agreement with Alamo Pharma Services, Inc. for the establishment and management of a national sales team for Mytesi™ (formerly known as Fulyzaq). Mytesi™, launched by Napo in October 2016, is approved by the U.S. FDA for the...